Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Back

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

- 15 February 2024 - 1 mins read

Ipsen S.A. – 2023 Consolidated Financial Statements

Attachment

Related Press Releases

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
24 April 2025 7 mins read

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
16 April 2025 6 mins read

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Ipsen publishes its 2024 Universal Registration Document
08 April 2025 4 mins read

Ipsen publishes its 2024 Universal Registration Document
Ipsen announces issuance of €500 million inaugural Rated Public Bond
19 March 2025 7 mins read

Ipsen announces issuance of €500 million inaugural Rated Public Bond
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
12 March 2025 5 mins read

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
13 February 2025 6 mins read

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
03 December 2024 6 mins read

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
18 November 2024 12 mins read

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
15 November 2024 12 mins read

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
23 October 2024 4 mins read

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance